☆ 4.5 Review

Approaches to Oligometastatic Renal Cell Carcinoma

CURRENT ONCOLOGY REPORTS (2023)

Related references

Note: Only part of the references are listed.

Review Urology & Nephrology

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Jennifer Le Guevelou et al.

Summary: Stereotactic ablative radiotherapy (SABR) has potential in the management of metastatic renal cell carcinoma (mRCC) as a part of multimodal approaches. SABR can achieve complete remission of metastatic lesions, prolong the duration of systemic therapy, improve treatment response in polymetastatic patients, and reduce tumor burden in some cases. The impact on renal function is unclear. Overall, the combination of SABR and systemic agents is well-tolerated.

EUROPEAN UROLOGY FOCUS (2023)

Add to Collection

Article Urology & Nephrology

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial

Shankar Siva et al.

Summary: The RAPPORT trial investigated the combination of high-dose precision radiotherapy and a short course of immunotherapy in patients with low-volume metastatic kidney cancer. The results showed that this treatment regimen was well tolerated, with excellent cancer control in known disease sites, and a proportion of patients were free from cancer relapse in the longer term. These findings are encouraging and warrant further investigation.

EUROPEAN UROLOGY (2022)

Add to Collection

Editorial Material Urology & Nephrology

Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change?

Shankar Siva et al.

Summary: In this first of its kind trial for oligometastatic renal cell carcinoma, stereotactic ablative body radiotherapy was successfully delivered instead of systemic therapy. This strategy should be considered for selected patients with oligometastatic RCC.

NATURE REVIEWS UROLOGY (2022)

Add to Collection

Editorial Material Oncology

Stereotactic body radiotherapy as first-line treatment for oligometastatic renal cell cancer

Matthias Guckenberger

STRAHLENTHERAPIE UND ONKOLOGIE (2022)

Add to Collection

Article Oncology

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

W. Kimryn Rathmell et al.

Summary: The article provides recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC), including diagnosis, treatment, and participation in clinical trials.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus

Thomas Zilli et al.

Summary: Oligometastatic prostate cancer is a new and emerging treatment field, with a lack of strong level I evidence. Despite this, metastasis-directed therapies are widely used in clinical practice. More consistent treatment indications and radiotherapy practices are needed until mature results of randomized trials are available.

RADIOTHERAPY AND ONCOLOGY (2022)

Add to Collection

Article Oncology

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases

Paolo Sogono et al.

Summary: The study showed that single-fraction stereotactic body radiation therapy is safe and effective for patients with oligometastatic disease, reducing the number of attendances and improving efficiency. Patients had high overall survival rates and a significant proportion remained treatment-free for several years after therapy.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Add to Collection

Article Oncology

Trends in Diagnosis and Treatment of Metastatic Cancer in the United States

Eric J. Lehrer et al.

Summary: Metastatic cancer has shown unique epidemiological patterns and improved survival rates in this study. Overall, there has been an increase in the use of systemic therapies and a decrease in the use of local therapies.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)

Add to Collection

Article Urology & Nephrology

Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma

Stephanie G. C. Kroeze et al.

Summary: The study evaluated the safety and efficacy of stereotactic radiotherapy in mRCC patients receiving targeted therapy or immunotherapy. The results showed that the combined treatment was safe and effective, with good local metastasis control and survival rates.

BJU INTERNATIONAL (2021)

Add to Collection

Review Oncology

(Oligo)metastasis as a Spectrum of Disease

Stanley Gutiontov et al.

Summary: The understanding of oligometastatic state has evolved, emphasizing that cancer metastasis represents a spectrum of disease. Recent clinical trials have shown improvements in cancer-specific outcomes with the use of metastasis-directed local therapies. Biological aspects of oligometastases, including genetic, epigenetic, and immune determinants, were discussed along with considerations for future clinical trial design for patients with oligometastatic disease.

CANCER RESEARCH (2021)

Add to Collection

Editorial Material Urology & Nephrology

The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care

Jens Bedke et al.

Summary: The recent trials have shown improved survival benefits with immune checkpoint inhibitor combinations in advanced kidney cancer, particularly with lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, axitinib plus pembrolizumab, and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatments for advanced kidney cancer.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?

G. Marvaso et al.

Summary: This study evaluated the role of SBRT in synchronous and metachronous oligo metastatic RCC patients, showing that SBRT has a good local control effect and excellent tolerability in this patient population, allowing for a delay in the start of systemic therapy.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care?

Nicolas Magné et al.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial

Chad Tang et al.

Summary: This study investigated the feasibility and efficacy of radiotherapy to postpone systemic therapy for patients with oligometastatic renal cell carcinoma. Results showed that radiotherapy could defer systemic therapy initiation for select patients and allow sustained systemic therapy breaks, with good tolerance.

LANCET ONCOLOGY (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Focus on the expected quality of reporting in SBRT/radiosurgery prospective studies: how far have we come in 30 years?

Nicolas Vial et al.

Summary: The study aimed to evaluate the reporting quality of prospective trials on radiosurgery and SBRT, finding a decrease in reporting of crucial data such as randomisation information and ITT analysis in publications after 2010. Although information on patient inclusion and radiation doses was reported relatively well, reporting on radiotherapy characteristics and toxicities did not show improvement in the 2010s-2019s timeframe.

BRITISH JOURNAL OF RADIOLOGY (2021)

Add to Collection

Article Immunology

Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?

Patricia Martin-Romano et al.

Summary: The case study suggests that previous radiotherapy may have an impact on the immune response to immunotherapy in cancer patients, possibly due to differences in the immune microenvironment caused by radiotherapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Stereotactic body radiotherapy: Passing fad or revolution?

Alexis Vallard et al.

BULLETIN DU CANCER (2020)

Add to Collection

Review Oncology

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

Matthias Guckenberger et al.

LANCET ONCOLOGY (2020)

Add to Collection

Letter Oncology

To exploit the 5 'R' of radiobiology and unleash the 3 'E' of immunoediting: 'RE'-inventing the radiotherapy-immunotherapy combination

Elisabeth Daguenet et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies

Nicholas G. Zaorsky et al.

EUROPEAN UROLOGY ONCOLOGY (2019)

Add to Collection

Review Oncology

Definitions of oligometastatic disease and new treatment concepts

Manon Kissel et al.

BULLETIN DU CANCER (2018)

Add to Collection

Article Medicine, General & Internal

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

A. Mejean et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014

M. Stenman et al.

RADIOTHERAPY AND ONCOLOGY (2018)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Percutaneous microwave ablation for local control of metastatic renal cell carcinoma

Kimberly A. Maciolek et al.

ABDOMINAL RADIOLOGY (2018)

Add to Collection

Article Urology & Nephrology

Management of metastatic renal cell carcinomass

C. Rolley et al.

PROGRES EN UROLOGIE (2018)

Add to Collection

Article Oncology

Pooled Analysis of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK)

Shankar Siva et al.

CANCER (2018)

Add to Collection

Article Oncology

Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report

Julien Langrand-Escure et al.

ANTI-CANCER DRUGS (2016)

Add to Collection

Review Oncology

Radiotherapy for renal-cell carcinoma

Gert De Meerleer et al.

LANCET ONCOLOGY (2014)

Add to Collection

Article Oncology

Stereotactic body radiotherapy for multisite extracranial oligometastases Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease

Joseph K. Salama et al.

CANCER (2012)

Add to Collection

Article Oncology

Oligometastases revisited

Ralph R. Weichselbaum et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.